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Abstract
Background: Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims
to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients
with type 2 diabetes mellitus and early diabetic nephropathy.
Methods: Fetuin-A serum levels were assessed by ELISA in a cross-sectional setting in 153 patients with type 2
diabetes. Associations of fetuin-A with metabolic, inflammatory and vascular markers were studied. Atherosclerotic
burden was assessed by ankle-brachial-index (ABI) as well as detection of common carotid artery intima-media
thickness (IMT).
Results: Levels of fetuin-A were lower in male than in female patients (0.49 ± 0.15 vs. 0.56 ± 0.20 g/L, p = 0.02). In
addition, there was an inverse correlation with age (r = -0.20, P = 0.01). Bivariate correlations adjusted for age and
gender revealed no significant correlations with metabolic parameters, except for a weak inverse correlation with
serum adiponectin (r = -0.19, p = 0.02). Regarding parameters of micro- and macrovascular disease, fetuin-A was
significantly associated with ABI (r = 0.18, p = 0.04), while there was no association with IMT (r = -0.07, p = n.s).
Patients with an ABI < 0.9 had lower fetuin A levels than patients with an ABI 0.9-1.3 or > 1.3 (0.43 ± 0.10 vs. 0.52
± 0.17 vs. 0.54 ± 0.18 g/L p = 0.05). Neither GFR nor albuminuria were associated with fetuin-A serum levels.
Patients with prevalent neuropathy did not have altered fetuin-A levels compared to diabetic controls. In step-wise
logistic regression analysis including age, gender, HbA1c, total cholesterol, glomerular filtration rate and fetuin-A,
only total cholesterol (b = 0.01, p = 0.02) and fetuin-A (b = -5.99, p = 0.03) proved to be independent predictors of
an ABI < 0.9.
Conclusions: The results of this cross-sectional study suggest that lower fetuin-A levels are associated with
macrovascular late complications in high-risk type 2 diabetes patients while there are no associations of fetuin-A
with metabolic status or microvascular complications.
Background
Various biomarkers have been studied for identification
of type 2 diabetes (T2D) patients at micro- and macro-
vascular risk. Most of these markers are inflammatory,
metabolic or procoagulant molecules indicating an unfa-
vourable metabolic and vascular status in patients with
type 2 diabetes [1]. However, the different biomarkers
show large variations in risk prediction depending on
metabolic status and disease severity of the study groups
[2,3]. Recently published data imply, that most novel
biomarkers do not improve risk prediction when added
to models based on conventional risk scores [4] Yet,
associations of novel biomarkers such as fetuin-A with
metabolic markers or complications do help to under-
stand their role in the pathophysiology of vascular
disease.
In mice, fed a mineral/vitamin D-rich diet, knockout
of fetuin-A resulted in arterial or soft-tissue calcification
or both [5-7]. In humans, so far the available data has
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with mortality and CVD events in cohorts with end-
stage renal disease (ESRD) [8,9], while a population
based study linked high plasma fetuin-A levels to an
increased risk of myocardial infarction (MI) and
ischemic stroke (IS) [10]. Yet, we could not demonstrate
an association of fetuin-A with traditional cardiovascular
risk factors, cardiovascular outcome or the metabolic
syndrome in patients with manifest CHD in a 6-year fol-
low study [11]. Contradictory results have also been
published regarding the role of fetuin-A in macrovascu-
lar disease and patients with type 2 diabetes [12-14].
While some studies associated lower fetuin-A levels
with peripheral arterial disease (PAD) [12,13], others
observed an association of increased fetuin-A levels with
coronary artery calcification (CAC) [15].
So far, there is no data available for associations of
fetuin-A with parameters of microvascular dis-ease in
diabetes. To clarify the relation between fetuin-A and
microvascular complications in patients with type 2 dia-
betes and early diabetic nephropathy, we studied asso-
ciations with albuminuria, parameters of renal function
as well as diabetic neuropathy. In addition, the athero-
sclerotic burden of these patients was assessed by quan-
tification of the ankle-brachial index (ABI) and the
common carotid artery intima-media-thickness (IMT).
Methods
Study population and data collection
153 Patients with type 2 diabetes were recruited from
family practices being referred to the diabetes outpatient
clinic at the University Hospital Heidelberg for specialist
treatment. For eligibility, patients had to have a docu-
mented history of albuminuria in at least two separate
urine samples (urinary albumin > 20 mg/L as suggested
by current German and international guidelines for the
diagnosis of diabetic nephropathy [16] as previously
described [17]. Detailed patient characteristics are given
in Table 1. In all individuals, 24-h urine samples were
collected on 3 consecutive days and the mean of AER as
well as the MDRD formula for the estimation of the glo-
merular filtration rate [18] were taken for statistical eva-
luation of renal function. All blood values, as well as
ambulatory 24-h blood pressure values (given as mean
of 24 h), were taken on day 1. The study complied with
the Declaration of Helsinki, and all subjects gave written
informed consent. The study was approved by the ethics
committee of the Uni-versities of Heidelberg.
Clinical chemistry
Blood was drawn on day 1 in a fasting state under stan-
dardized conditions and stored at -80°C until analysis.
Serum fetuin-A was measured in duplicates by an ELISA
(Epitope Diagnostics, Inc., San Diego, USA) according to
the manufacturer’s protocol. The intra- and interassay
variations were 5.3 and 7.1%, respectively. FPG was mea-
sured by a glucose oxidase method. Triglyceride, total
cholesterol, and HDL cholesterol levels were quantified
by standard laboratory methods, and LDL cholesterol
levels were calculated by using the Friedewald formula.
A1C was measured by high-performance liquid chroma-
tography on a Variant II device (Bio-Rad Laboratories,
Munich, Germany). AER was assessed and performed in
three consecutive 24-h urinary collections. For collection
of the urine sample, a 3-l plastic container was used, and
t h ev o l u m eo fu r i n ew a sm e a s u r e dt ot h en e a r e s t5 0m l .
Albumin levels were determined by turbidimetry
(Siemens Healthcare Diagnostics, Eschborn, Germany).
AER was expressed as milligrams per 24 h.
Assessment of carotid atherosclerosis and ankle-brachial
index
IMT was detected using high-resolution B-mode ultra-
sound (Voluson 730 Kretz, Tiefenbach, Austria) of the
extracranial carotid arteries bilaterally under continuous
detection of the heart cycle using a three-lead electrocar-
diogram. The whole imaging and quantification procedure
was performed digitally (Voluson 730 Kretz, Tiefenbach,
Austria) at the time of study entry by a single investigator
blinded for clinical data. For the purpose of this study,
IMTs of the far wall of the common carotid artery were
detected in end-diastolic frames, ~10 mm proximal to the
carotid bulb, according to a previously described scanning
protocol [19]. The measurements were performed at four
points of both common carotid arteries avoiding areas of
atherosclerotic plaque formation. The mean of the result-
ing eight single measurements was taken as mean IMT for
statistical analyses in this study. The ABI was detected by
simultaneous measurement of the brachial and posterior
tibial artery systolic pressure using the 5 MHz Mini Dop-
plex® doppler device (Huntleigh Diagnostic Products,
Cardiff, UK). Pressure was taken at the posterior tibial
artery only and the lower ABI from both sides was taken
for analyses. Patients were further classified to have no
PAD (ABI 0.9-1.3), mediasclerosis (ABI > 1.3) or prevalent
PAD (ABI < 0.9). 151 patients qualified for statistical ana-
lyses regarding this endpoint.
Patients were considered to have significant neuropa-
thy when they had a vibration perception < 5/8 using a
Rydel-Seiffer graduated tuning fork (C-64 to C-128)
which was previously shown to be a reliable diagnostic
instrument for the detectiono fp e r i p h e r a ln e u r o p a t h y
[20]. The mean of measurements on both feet was taken
for evaluation.
Statistical analyses
Statistical analyses were performed using SPSS software
version 16.0 (SPSS, Chicago, IL). Spearman correlation
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between serum fetuin-A and the variables of interest.
Comparison between two or more sets of patients was
performed by independent t test or one-way ANOVA.
Multivariable linear and stepwise binary logistic regres-
sion analyses evaluated the association of serum fetuin-
A with the respective metabolic or vascular parameters.
Models were adjusted as given in the respective Table
or the Results section.
Results
Association of serum fetuin-A levels with cardiovascular
risk factors and renal function
Clinical and laboratory characteristics of patients with
type 2 diabetes and bivariate analyses of as-sociations
between different variables and serum fetuin-A are
given in Table 1. The overall mean serum level of
fetuin-A was 0.51 ± 0.17 g/L with a range of 0.30 to
1.07 g/L. In bivariate analysis, only age was signifi-
cantly and inversely associated with serum fetuin-A
levels (r = -0.20, p = 0.02). Male patients had signifi-
cantly lower fetuin-A levels (0.49 ± 0.15 vs. 0.56 ± 0.20
g/L, p = 0.02). Table 2 shows the association of fetuin-
A levels with metabolic pa-rameters and markers
of vascular disease and renal function. Apart from
adiponectin, which was inversely and signifi-cantly
associated with fetuin-A levels (r = -0.188, p = 0.02),
no other metabolic variable significantly correlated in
this group of type 2 diabetes patients with vascular late
complications.
Table 1 Patients Characteristics
Type 2 diabetic patients Serum fetuin-A*
rp
n 153
Gender (male) 116 (74)§ - -
Age (Years) 59 ± 8 -0.201# 0.01
BMI (kg/m
2) 33 ± 6 -0.125 n.s.
Systolic BP (mmHg) 136 ± 19 0.104 n.s.
Diastolic BP (mmHg) 80 ± 8 0.125 n.s.
Duration of diabetes (years) 12 ± 8 -0.016 n.s.
Current smoker (yes) 25 (16) - -
Patients on ACE-inhibitor or angiotensin receptor blocker (yes: n;%) 128 (82) - -
Patients on Statin (yes:n;%) 89 (57) - -
Patients on Beta-Blockers (yes:n;%) 76 (49) - -
Patients receiving antihypertensive drugs (%) 137 (90) - -
Patients receiving > 2 antihypertensive drugs (%) 73 (48) - -
Patients on Insulin Treatment (yes:n;%) 91 (58) - -
HbA1c (%) 7.3 ± 1.2 -0.045 n.s.
Fasting Glucose (mg/dL) 144 ± 50 -0.022 n.s.
Serum Creatinine (mg/dL) 0.89 ± 0.3 0.017 n.s.
Serum Albumin (g/L) 45 ± 3 -0.006 n.s.
Serum Fetuin A (g/L) 0.51 ± 0.17
* log transformed data for analysis
# adjusted for gender, all other correlations are partially adjusted for age and gender
§ male vs. female: 0.49 ± 0.15 vs. 0.56 ± 0.20 g/L, p = 0.02
Table 2 Associations of Fetuin A with Metabolic
Parameters, markers of vascular disease and renal
function
Serum fetuin-A*
r# p
Waist/Hip-Ratio 1.02 ± 0.08 0.069 n.s.
Triglycerides (mg/dL) * 223 ± 307 0.05 n.s.
Cholesterol (mg/dL) 189 ± 56 -0.001 n.s.
HDL (mg/dL) 45.6 ± 13.4 -0.034 n.s.
Adiponectin (μg/mL) * 10.3 ± 6.6 -0.188 0.02
hsCRP (mg/L)* 3.9 ± 5.4 0.063 n.s.
Intima-Media-Thickness (mm) 0.87 ± 0.15 -0.070 n.s.
Ankle-Brachial Index 1.01 ± 0.18 0.175 0.04
Estimated Glomerular Filtration
Rate (MDRD, ml/min)
97 ± 32 -0.017 n.s.
Albumin Excretion (mg/24 h)* 154 ± 371 0.096 n.s.
* log transformed data for analysis
# partially adjusted for age and gender
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serum fetuin-A levels with IMT, the glomerular filtra-
tion rate (GFR by MDRD) or the albumin excretion.
However, serum fetuin-A was positively associated with
the ABI (r = 0.18, p = 0.04). In multivariable linear
regression analysis with fetuin-A as the dependent vari-
able, age (b = -0.203, p = 0.024) and adiponectin (b =
-0.192, p = 0.03) were independently associated with
fetuin-A. A boderline significance was seen with gender
(b = 0.228, p = 0.06). No associations of fetuin-A were
seen with BMI (b = -0.131, p = 0.12), HbA1c (b =
-0.004, p = 0.96) and albumin (b = -0.02, P = 0.98).
Associations of fetuin-A levels with prevalent macro-
vascular disease were studied. While there were no asso-
ciations of fetuin-A with IMT as a surrogate marker of
atherosclerosis (r = -0.11, p = 0.2, Figure 1a), patients
with an ABI < 0.9 had lower fetuin A levels than
patients with an ABI 0.9-1.3 or > 1.3 (0.43 ± 0.10 vs.
0.52 ± 0.17 vs. 0.54 ± 0.18 g/L p = 0.05). (Figure 1b). In
addition, concentrations of fetuin-A were quantified in
patients with or without a history of macrovascular dis-
ease such as coronary artery disease, stroke and periph-
eral artery disease. In this analysis, patients with a
history of macrovascular disease (n = 102) revealed a
trend towards lower levels of fetuin-A compared to
patients without prevalent macrovascular disease
(n = 51) (0.47 ± 0.16 vs 0.52 ± 0.17 g/L, p = 0.08),
(Figure 2a). In a binary stepwise logistic regression ana-
lysis excluding patients with an ABI > 1.3, only total
cholesterol (b = 0.01, p = 0.02) and fetuin-A (b = -5.99,
p = 0.03) proved to be independent predictors of an
ABI < 0.9, while age, gender, HbA1c, and glomerular fil-
tration rate were not sig-nificantly associated with PAD.
We further investigated the association of fetuin-A
levels with prevalent polyneuropathy (PNP). Fe-tuin-A
serum levels did not differ among patients with (n = 69)
vs. without (n = 84) PNP (0.50 ± 0.15 vs. 0.52 ± 0.16
μg/mL, p = 0.58) (Figure 2b). Likewise, fetuin-A concen-
trations were not associated with the degree of 24 h
albumin excretion as an additional marker of microvas-
cular disease in these patients with early diabetic
nephropathy (Table 2).
Discussion
This study demonstrates that lower fetuin-A levels seem
to be associated with prevalent macrovas-cular disease
Figure 1 A: Serum fetuin-A levels and macrovascular disease (Intima Media Thickness). Scatter plot showing the relationship between
serum fetuin-A levels and IMT. Data as given by Spearman correlation coefficient. B: Serum fetuin-A levels and ankle-brachial index (ABI).
Fetuin-A levels were compared between groups stratified by ABI.(< 0.90, 0.90-1.30, and > 1.30). Data +/-SD, p-value as given by one- way
ANOVA.
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ker of atherosclerotic burden. Furthermore, we could
show for the first time, that fetuin-A serum levels are
not associated with microvascular complications in
patients with early diabetic nephropathy. In addition,
fetuin-A levels do not correlate with metabolic para-
meters in our type 2 diabetes patients with prevalent
late complications.
Fetuin-A was shown to act as a natural inhibitor of
the insulin receptor tyrosine kinase in liver and skeletal
muscle, and fetuin knock-out mice displayed improved
insulin sensitivity [21]. Different observational studies
have proposed that high serum fetuin-A levels are asso-
ciated with the presence or development of the meta-
bolic syndrome suggesting fetuin-A as a risk factor for
this condition [10,22,23]. Moreoever, fetuin-A com-
plexes with calcium and phosphorus in the circulation
and prevents the precipitation of these minerals in
serum [5,6]. Fetuin-A is regarded as marker for vascular
inflammation and as one of the most potent negative
regulators of vascular ossification - calcification [24,25].
In animals lacking the fetuin-A gene, the aorta was
found to be spared of cal-cification and fibrosis, whereas
peripheral vessels in the skin and kidney showed evi-
dence of extensive calcification, and the small artery
involvement preceded the impairment of renal function
[6,26]. The data presented herein allows to speculate,
that fetuin-A could play a role in the development of
prevalent macrovascular disease in type 2 diabetes, yet
possible mechanisms remain unclear. In line with this
hypothesis, Emoto et al. showed a possible effect of
fetuin-A on inhibiting the calcification of atherosclerotic
calcified plaques (CP) independently of renal impair-
ment [13]. In their study including less advanced type 2
diabetes patients without nephropathy and of which
32% were even on dietary treatment, fetuin-A levels
were significantly lower in patients with atherosclerotic
CP of the common carotid and femoral arteries than in
those without CP. Our data in more advanced micro-
and macrovascular disease suggests that fetuin-A might
p l a yar o l ei nt h ed e v e l o p m e n to fv a s c u l a rs t e n o s i s ,
while there were no associations with early lesions indi-
cated by IMT. It needs to be emphasized in this context,
that the measurement of IMT is performed in areas
with no atherosclerotic plaque. However, patients in this
study have a number of possible confounders for the
association of fetuin-A and IMT like medications
including insulin as well as prevalent microvascular dis-
ease. The results presented are also in line with previous
data [12] showing that circulating fetuin-A was lower in
38 subjects with type 2 diabetes and an ABI < 0.9, com-
pared with 700 diabetes controls. Somehow contradic-
tory, another study showed a direct relation between
serum fetuin-A levels and coronary artery calcification
(CAC) evaluated by electron beam computed tomogra-
phy [15]. Like IMT, CAC is a surrogate marker for
Figure 2 A: Serum fetuin-A levels and cardiovascular disease (CVD). Patients were stratified by history of any cardiovascular disease (i.e.
PAD, CAD or stroke). Data +/-SEM, p-value as given by independent T-Test. B: Serum fetuin-A levels in patients with diabetic neuropathy.
Data +/-SEM, p-value as given by independent T-Test.
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CHD in terms of vascular stenosis. In addition, the data
on CAC were obtained from African Americans and
Latinos and fetuin-A levels were previously shown to
differ among ethnic groups [22,27]. Reviewing the exist-
ing data as well as the results obtained in this study, it
may be assumed that fetuin-A levels are lower in type 2
diabetes patients with stenosing arterial disease, possibly
independent of the localization.
Our results are in contrast to findings in non- diabetic
subjects [28], as well as several cross-sectional studies
which showed an association of high fetuin-A levels
with impaired glucose tolerance, lipid metabolism and
markers of vascular disease [10,22,23]. The advanced
type 2 diabetes patients in this study showed no associa-
tions of metabolic parameters with fetuin-A except and
inverse correlation of fetuin-A levels with serum adipo-
nectin which is in line with previous experimental data
showing a decrease in adiponectin expression as well as
circulating adiponectin levels in mice treated with
fetuin-A [21]. Yet, associations of fetuin-A with meta-
bolic parameters can be confounded by many of the
medications in the subjects studied herein. In a middle-
aged non- diabetic population of which the majority was
female, increased fetuin-A levels were associated with
increased IMT [28]. Again, a recently published study in
patients without diabetes and renal impairment demon-
strated decreased fetuin-A serum levels in patients suf-
fering from advanced three-vessel disease compared
with those without stenosis [29]. These finding go in
line with our assumption of reduced fetuin-A serum
levels in patients with prevalent vascular disease.
Taken together, we assume a biphasic association of
fetuin-A with vascular disease: relatively healthy diabetic
and non-diabetic patients without pre-existing vascular
disease [10,23] show associations of higher fetuin-A
with metabolic and vascular risk, while patients with
prevalent vascular disease have decreased fetuin-A
levels. Hence, the currently available data implies that
effects of fetuin-A may be of greater importance in the
very early phases of atherosclerosis, a pattern known
from other CHD risk factors, such as C-reactive protein
or adiponectin, which seem to be better predictors in
primary prevention [30,31]. Yet, future experimental stu-
dies will have to reveal the mechanisms by which fetuin-
A could influence the early atherosclerotic process.
Since mice deficient for the fetuin-A gene showed a
distinct pattern of small caliber vessel and kidney calcifi-
ciation, we studied associations of parameters of micro-
vascular disease with fetuin-A for the first time in this
study. Interestingly, we did not find any associations,
neither with the degree of albumin excretion or renal
function, nor with the prevalance of diabetic neuropathy.
This suggests, that fetuin-A does not play a significant
role in the development of these entities of diabetes
complications.
We recognize the limitations of the present study. Our
approach is limited by the small samples size. Therefore,
especially the data for associations with microvascular
disease and renal function in type 2 diabetes will have
to be reproduced in larger groups. Moreover, the cross-
sectional design needs cautious interpretation of data
and there is no prospective data for primary or second-
ary prevention in diabetes available.
Conclusions
In this study, low plasma fetuin-A levels predict PAD in
type 2 diabetes with early diabetic neph-ropathy while
there are no associations of fetuin-A with markers of
microvascular disease in these patients.
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